13,14-dihydro-15-keto Prostaglandin E2 - CAS 363-23-5

13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) serves as the predominant metabolite of PGE2 in plasma, created through a 15-keto PGE2 intermediate by the action of 15-oxo-PG Δ13 reductase. Unlike its precursor PGE2, this compound exhibits poor binding affinity towards EP2 and EP4 PGE2 receptors (Ki values of 12 and 57 μM, respectively) in CHO cells and fails to stimulate adenylate cyclase activity therein (EC50s >18 and >38 μM, respectively) . Concentrations of 13,14-dihydro-15-keto PGE2 are notably higher in the plasma of pregnant women during their third trimester and at labor and delivery stages, whereas its levels are found to be reduced in the tumor tissues of patients with non-small cell lung cancer (NSCLC) compared to adjacent healthy tissue.

Others, 5-HT Receptor, Endogenous Metabolite

GPCR/G Protein, Metabolism, Neuroscience, Others

363-23-5

C20H32O5

352.5

C(/C=C\CCCC(O)=O)[C@@H]1[C@@H](CCC(CCCCC)=O)[C@H](O)CC1=O

-20°C

Ice Packs

Small Compound